Antoine Yrondi1, Marie Sporer2, Patrice Péran3, Laurent Schmitt2, Christophe Arbus4, Anne Sauvaget5. 1. Psychiatric Department, CHU Toulouse-Purpan, 330 Avenue de Grande Bretagne, 31059 Toulouse, France; Toulouse NeuroImaging Center, ToNIC, University of Toulouse, Inserm, UPS, France. Electronic address: antoineyrondi@gmail.com. 2. Psychiatric Department, CHU Toulouse-Purpan, 330 Avenue de Grande Bretagne, 31059 Toulouse, France. 3. Toulouse NeuroImaging Center, ToNIC, University of Toulouse, Inserm, UPS, France. 4. Psychiatric Department, CHU Toulouse-Purpan, 330 Avenue de Grande Bretagne, 31059 Toulouse, France; Toulouse NeuroImaging Center, ToNIC, University of Toulouse, Inserm, UPS, France. 5. CHU Nantes, Addictology and Liaison Psychiatry Department, Neuromodulation Unit in Psychiatry, Nantes, France.
Abstract
BACKGROUND: The management and treatment of major depressive disorder are major public health challenges, the lifetime prevalence of this illness being 4.4%-20% in the general population. Major depressive disorder and treatment resistant depression appear to be, in part, related to a dysfunction of the immune response. Among the treatments for depression ECT occupies an important place. The underlying cerebral mechanisms of ECT remain unclear. OBJECTIVES/HYPOTHESIS: The aim of this review is to survey the potential actions of ECT on the immuno-inflammatory cascade activated during depression. METHODS: A systematic search of the literature was carried out, using the bibliographic search engines PubMed and Embase. The search covered articles published up until october 2017. The following MESH terms were used: Electroconvulsive therapy AND (inflammation OR immune OR immunology). RESULTS: Our review shows that there is an acute immuno-inflammatory response immediately following an ECT session. There is an acute stress reaction. Studies show an increase in the plasma levels of cortisol and of interleukins 1 and 6. However, at the end of the course of treatment, ECT produces, in the long term, a fall in the plasma level of cortisol, a reduction in the levels of TNF alpha and interleukin 6. LIMITATIONS: One of the limitations of this review is that a large number of studies are relatively old, with small sample sizes and methodological bias. CONCLUSION: Advances in knowledge of the immuno-inflammatory component of depression seem to be paving the way towards models to explain the mechanism of action of ECT.
BACKGROUND: The management and treatment of major depressive disorder are major public health challenges, the lifetime prevalence of this illness being 4.4%-20% in the general population. Major depressive disorder and treatment resistant depression appear to be, in part, related to a dysfunction of the immune response. Among the treatments for depression ECT occupies an important place. The underlying cerebral mechanisms of ECT remain unclear. OBJECTIVES/HYPOTHESIS: The aim of this review is to survey the potential actions of ECT on the immuno-inflammatory cascade activated during depression. METHODS: A systematic search of the literature was carried out, using the bibliographic search engines PubMed and Embase. The search covered articles published up until october 2017. The following MESH terms were used: Electroconvulsive therapy AND (inflammation OR immune OR immunology). RESULTS: Our review shows that there is an acute immuno-inflammatory response immediately following an ECT session. There is an acute stress reaction. Studies show an increase in the plasma levels of cortisol and of interleukins 1 and 6. However, at the end of the course of treatment, ECT produces, in the long term, a fall in the plasma level of cortisol, a reduction in the levels of TNF alpha and interleukin 6. LIMITATIONS: One of the limitations of this review is that a large number of studies are relatively old, with small sample sizes and methodological bias. CONCLUSION: Advances in knowledge of the immuno-inflammatory component of depression seem to be paving the way towards models to explain the mechanism of action of ECT.
Authors: Malcolm P Forbes; Adrienne O'Neil; Melissa Lane; Bruno Agustini; Nick Myles; Michael Berk Journal: Drugs Aging Date: 2021-04-29 Impact factor: 3.923
Authors: Mike M Schmitgen; Katharina M Kubera; Malte S Depping; Henrike M Nolte; Dusan Hirjak; Stefan Hofer; Julia H Hasenkamp; Ulrich Seidl; Bram Stieltjes; Klaus H Maier-Hein; Fabio Sambataro; Alexander Sartorius; Philipp A Thomann; Robert C Wolf Journal: Eur Arch Psychiatry Clin Neurosci Date: 2019-07-05 Impact factor: 5.270
Authors: Helena M Abelaira; Thayse Rosa; Airam B de Moura; Natalia M Andrade; Nicoly S Martinello; Larissa R Maciel; Maria Eduarda M Botelho; Laura A Borba; Beatriz C Chede; Camila O Arent; Larissa Joaquim; Sandra Bonfante; Lucinéia G Danielski; Talita Tuon; Fabricia Petronilho; João Quevedo; Gislaine Z Réus Journal: Mol Neurobiol Date: 2022-01-07 Impact factor: 5.590
Authors: Alessio Squassina; Mirko Manchia; Claudia Pisanu; Raffaella Ardau; Carlo Arzedi; Alberto Bocchetta; Paola Caria; Cristina Cocco; Donatella Congiu; Eleonora Cossu; Tinuccia Dettori; Daniela Virginia Frau; Mario Garzilli; Elias Manca; Anna Meloni; Maria Antonietta Montis; Andrea Mura; Mariella Nieddu; Barbara Noli; Pasquale Paribello; Federica Pinna; Renato Robledo; Giovanni Severino; Valeria Sogos; Maria Del Zompo; Gian Luca Ferri; Caterina Chillotti; Roberta Vanni; Bernardo Carpiniello Journal: Neuropsychopharmacology Date: 2020-09-12 Impact factor: 7.853
Authors: Jennifer L Kruse; Richard Olmstead; Gerhard Hellemann; Benjamin Wade; Janina Jiang; Megha M Vasavada; John O Brooks Iii; Eliza Congdon; Randall Espinoza; Katherine L Narr; Michael R Irwin Journal: Brain Behav Immun Date: 2020-05-29 Impact factor: 19.227